{"name":"Clinvest","slug":"clinvest","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"almotriptan or pseudoephedrine","genericName":"almotriptan or pseudoephedrine","slug":"almotriptan-or-pseudoephedrine","indication":"Acute migraine with or without aura, with associated nasal congestion","status":"marketed"}]}],"pipeline":[{"name":"almotriptan or pseudoephedrine","genericName":"almotriptan or pseudoephedrine","slug":"almotriptan-or-pseudoephedrine","phase":"marketed","mechanism":"This is a combination product containing almotriptan (a selective 5-HT1B/1D receptor agonist for migraine) and pseudoephedrine (a sympathomimetic nasal decongestant).","indications":["Acute migraine with or without aura, with associated nasal congestion"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQbnYzbVhaQ0JrY2xvbTI0WkplNDlwYXYtM3UzOEc0WGQ1U3JpaTF2SjVwbjZlNXQ5eUlhb3dCVTlub2xOSm53YmZHQkdpMkJyZkZ1NGE4RzZpTGluY2hQWkU4aTNKMmoyN3dEY2JsaGg0aFNxVUdaU0xOaTJaUlZGSTYyTHdXU1hyVDRtcG9oVEl5Skd3NnNJNk9hdnF1T1RlazQwcg?oc=5","date":"2025-11-30","type":"pipeline","source":"دزاير توب","summary":"Algeria Positions Itself as a Future Pharmaceutical Powerhouse in Africa - دزاير توب","headline":"Algeria Positions Itself as a Future Pharmaceutical Powerhouse in Africa - دزاير توب","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxNVzR1dU5nLXIxVWJ4NHhDcnMzYzJxUVRmUDlqVEJrODd5VklKUjRlTzFpZWZyM3ViS3UzTDNxRV9iM2JCSGV1ZG8wM3VFM3FnUzVvZ0RpUkRyQmdPQk50TmY1MHpkZ3IzdnZIdnlqQVJfZWdvODhkRXhDSVFIYUE5YV81NUw0WkFBMkR6LXdkdGoxVzRpVnJaOFI2TXQ4dUtOUXV4TnJHMUthcHFUQkhxQnFDYy1YMXhaQ1Nua1pHZWNDNUx0TWNORGtpWFd4bGJaM0hQV0lFMlUzd0Y1MndPNGF4VVl3M3R0ODNWZWV4ZG9zQVJkT285aHQ5VnIxdTBKdHdWQkhR?oc=5","date":"2024-02-29","type":"trial","source":"PR Newswire","summary":"Headlands Research Acquires Clinical Trial Site Pharmasite Research, Enhancing Therapeutic Expertise in Key Competencies - PR Newswire","headline":"Headlands Research Acquires Clinical Trial Site Pharmasite Research, Enhancing Therapeutic Expertise in Key Competencies","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}